Biotech pauses trial after second patient death linked to gene therapy

washingtonpost.com/business/2025/06/16/sarepta-elevidys-duchenne-patient-death

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

This story appeared on washingtonpost.com, 2025-06-16 21:20:51.
The Entire Business World on a Single Page. Free to Use →